Announced details
Slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer's disease (early Alzheimer's disease)
Approximately 15 seconds per pen. Incidence of systemic reactions associated with injection: 1.4%.
Leqembi has been approved in 53 countries and regions and is under application review in 6 countries. Approval of the SC formulation is the third such approval worldwide.
Eisai and Biogen have been partners in the joint development and commercialization of Alzheimer's disease treatments since 2014, and will jointly commercialize and promote lecanemab. Eisai leads development and regulatory submissions globally and holds final decision-making authority.
A biotechnology company headquartered in Cambridge, Massachusetts, United States. Founded in 1978, it is led by CEO Christopher A. Viehbacher.
The impact on the earnings forecast for the fiscal year ending March 2027 is minor, and there is no change to the earnings forecast announced on 15 May 2026.
The company does not address Contract Value / Offering price.
Results from the 18-month core Clarity AD study, the subcutaneous administration substudy of the long-term extension (LTE) study, and integrated modeling and simulation analyses. Reference articles were published in Nat Commun, Int J Mol Sci, and Molecular Psychiatry.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Leqembi Subcutaneous 250 mg Pen, Leqembi (lecanemab) |
| Counterparty | Biogen Inc. (Nasdaq: BIIB) |
| Counterparty overview | A biotechnology company headquartered in Cambridge, Massachusetts, United States. Founded in 1978, it is led by CEO Christopher A. Viehbacher. |
| Relationship with the Company | Eisai and Biogen have been partners in the joint development and commercialization of Alzheimer's disease treatments since 2014, and will jointly commercialize and promote lecanemab. Eisai leads development and regulatory submissions globally and holds final decision-making authority. |
| Contract Date | 2014 (partnership for the joint development and commercialization of Alzheimer's disease treatments) |
| Applicable area | Slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer's disease (early Alzheimer's disease) |
| Quantitative Effects | Approximately 15 seconds per pen. Incidence of systemic reactions associated with injection: 1.4%. |
| Usage history | Leqembi has been approved in 53 countries and regions and is under application review in 6 countries. Approval of the SC formulation is the third such approval worldwide. |
| Impact on Business Performance | The impact on the earnings forecast for the fiscal year ending March 2027 is minor, and there is no change to the earnings forecast announced on 15 May 2026. |
| Source | Results from the 18-month core Clarity AD study, the subcutaneous administration substudy of the long-term extension (LTE) study, and integrated modeling and simulation analyses. Reference articles were published in Nat Commun, Int J Mol Sci, and Molecular Psychiatry. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To enable at-home administration, reduce administration time, the burden of hospital visits, and constraints on going out and traveling, and improve the efficiency of healthcare resources.